ATG-Fresenius S

ATG-Fresenius S Uses, Dosage, Side Effects, Food Interaction and all others data.

Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.

Antithymocyte Globulin (ATG) is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation. ATG reduces the host immune response against tissue transplants or organ allografts.

ATG-Fresenius S
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	ATG-Fresenius S
Generic	Antithymocyte immunoglobulin (rabbit)
Antithymocyte immunoglobulin (rabbit) Other Names	Anti-human thymocyte immunoglobulin, rabbit, Anti-T-lymphocyte immune globulin, rabbit, Anti-thymocyte globulin (rabbit), Anti-thymocyte globulin rabbit, Antithymocyte immunoglobulin, Lapine T-lymphocyte immune globulin, Rabbit anti-human thymocyte globulin, Rabbit anti-human thymocyte globulin (rATG), Rabbit anti-human thymocyte immunoglobulin, Rabbit anti-thymocyte immunoglobulin, Rabbit antithymocyte globulin, Rabbit ATG, rATG, Thymoglobulin, Thymoglobuline
Type
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

ATG-Fresenius S is a purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants.

For prevention of renal transplant rejection

ATG-Fresenius S is also used to associated treatment for these conditions: Acute cellular rejection, Antibody-mediated Rejection, Kidney Transplant Rejection, Myelodysplastic Syndrome, Induction therapy in renal transplantation

How ATG-Fresenius S works

Binds to multiple, T-cell specific antigens leading to T-lymphocyte cell death via complement mediated cytotoxicity or apoptosis.

Toxicity

Not known whether ATG (rabbit) distributes into human milk; however, other immunoglobulins are distributed into human milk.

Food Interaction

No interactions found.

Elimination Route

T-cell depletion usually observed within 1 day after initiating therapy. Average 21.5 and 87 mcg/mL 4–8 hours post-infusion after first and last IV doses, respectively, when given for 7–11 days.